https://register.epo.org/application?number=EP17783057
AffaMed Therapeutics Announced Top-Line Results From Real-World Study In China Evaluating The Safety And Efficacy Of DEXTENZA In Patients After Cataract Surgery; NOTE: AffaMed Therapeutics Has A Licensing Agreement With Ocular Therapeutix, Inc.
AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in
